Opinion
Video
Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL
Author(s):
Panelists discuss how they approach treatment selection for multi-refractory chronic lymphocytic leukemia (CLL) patients, considering factors such as prior therapy responses, patient fitness, and disease characteristics to guide choices among available options, including CAR T-cell therapy, while also addressing the limitations and challenges associated with each treatment modality in their decision-making process.
Video content above is prompted by the following:
- Which treatment options do you offer to your multi-refractory CLL patients and how do you select among available therapies?
- What key factors guide your decision to use CAR T-cell therapy in the R/R setting and what criteria do you use to select patients for this treatment?
- What are some limitations or challenges associated with these therapies and how do you weigh these into your
Related Videos
Related Content
